

# Pei Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6093569/publications.pdf>

Version: 2024-02-01

91  
papers

898  
citations

643344

15  
h-index

685536

24  
g-index

98  
all docs

98  
docs citations

98  
times ranked

1075  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	3.2	9
2	First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2022, 13, 821363.	1.6	8
3	Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4111-4120.	1.1	2
4	Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6. <i>Frontiers in Pharmacology</i> , 2021, 12, 617265.	1.6	1
5	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BlyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105704.	1.9	6
6	Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 645130.	1.6	4
7	Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 160, 105752.	1.9	0
8	A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 387-396.	1.1	0
9	Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial. <i>Frontiers in Endocrinology</i> , 2021, 12, 779365.	1.5	4
10	Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population. <i>Journal of Diabetes Investigation</i> , 2021, , .	1.1	1
11	Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4704.	0.8	3
12	Application of LC-MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 1635-1646.	0.6	0
13	Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). <i>BMC Endocrine Disorders</i> , 2020, 20, 57.	0.9	2
14	UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 367-378.	0.6	1
15	A UHPLC-MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 583-596.	0.6	1
16	Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. <i>Clinical Therapeutics</i> , 2020, 42, 614-624.	1.1	57
17	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105281.	1.9	9
18	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 6.	6.9	13

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 617122.	1.6	1
20	An ultra HPLC-MS/MS method for quantification of hypidon hydrochloride (YL-0919) and application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 1243-1254.	0.6	1
21	CX1003 quantification by ultra-performance LC-MS/MS in human plasma and its application to a pharmacokinetic study in solid tumor patients. <i>Bioanalysis</i> , 2019, 11, 1483-1493.	0.6	1
22	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104942.	1.9	7
23	Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography-MS/MS and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 773-784.	0.6	0
24	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 643-651.	1.1	9
25	SAT0139... A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS... 2019...		2
26	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 20-29.	1.4	1
27	Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. <i>Biomedical Chromatography</i> , 2019, 33, e4420.	0.8	6
28	Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 32-40.	1.4	1
29	First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study. <i>Blood</i> , 2019, 134, 2878-2878.	0.6	3
30	An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 1-8.	1.4	6
31	Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 744-750.	0.8	7
32	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018, 13, 968-977.	0.5	50
33	Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1307-1323.	1.6	10
34	A validated UPLC-MS/MS method for the quantitation of an unstable peptide, monocyte locomotion inhibitory factor (MLIF) in human plasma and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 75-83.	1.4	5
35	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 91-105.	1.4	1
36	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for <i>CYP2D6</i> . <i>Xenobiotica</i> , 2018, 48, 459-466.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Simultaneous determination of morphineâ€“glucuronide, morphineâ€“glucuronide and morphine in human plasma and urine by ultraâ€“performance liquid chromatographyâ€“tandem mass spectrometry: Application to M6G injection pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018, 32, e4066.	0.8	2
38	Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2018, 9, 1316.	1.6	22
39	Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 4047-4057.	2.0	7
40	Development of an HPLCâ€“MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. <i>Bioanalysis</i> , 2018, 10, 1439-1454.	0.6	6
41	Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. <i>Frontiers in Pharmacology</i> , 2018, 9, 991.	1.6	14
42	Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 189-200.	1.4	2
43	A highâ€“performance liquid chromatographyâ€“tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multipleâ€“dose pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018, 32, e4324.	0.8	7
44	Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. <i>Clinical Drug Investigation</i> , 2018, 38, 901-908.	1.1	3
45	Development and validation of a UPLCâ€“MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4365.	0.8	19
46	Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLCâ€“MS/MS and its application to a PK study. <i>Bioanalysis</i> , 2018, 10, 863-875.	0.6	9
47	Penetration of the bloodâ€“brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018, 122, 1-6.	0.9	17
48	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21108-e21108.	0.8	0
49	Development and validation of a UPLCâ€“MS/MS method for simultaneous determination of fotagliptin and its two major metabolites in human plasma and urine. <i>Bioanalysis</i> , 2017, 9, 381-393.	0.6	7
50	Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 100, 87-93.	1.9	4
51	Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 78-83.	1.4	23
52	Development of an UPLCâ€“MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 205-214.	1.4	13
53	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. <i>Clinical Therapeutics</i> , 2017, 39, 1313-1319.	1.1	4
54	An LCâ€“MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 141, 9-18.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process. <i>Clinical Pharmacokinetics</i> , 2017, 56, 925-939.	1.6	7
56	Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 33-40.	1.2	6
57	A UPLC-MS/MS method for quantification of 5 $\alpha$ -androst-3 $\beta$ ,5,6 $\beta$ -triol in human plasma: development, validation and its application in clinical pharmacokinetic study. <i>Bioanalysis</i> , 2017, 9, 873-885.	0.6	1
58	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30 $\times$ 90 $\times$ mg in healthy Chinese volunteers. <i>Xenobiotica</i> , 2017, 47, 592-599.	0.5	3
59	Development and validation of a rapid and sensitive UPLC-MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 1-6.	1.4	14
60	Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT $\times$ 18 in Chinese Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 948-959.	1.0	16
61	Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2016, 36, 463-470.	1.1	5
62	Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 92, 131-136.	1.9	5
63	A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. <i>Xenobiotica</i> , 2016, 46, 1105-1111.	0.5	10
64	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 8-14.	1.2	2
65	Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT $\times$ 18, a novel BLYS/APRIL fusion protein, in patients with rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 41-52.	1.1	14
66	Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 1869-1879.	1.1	15
67	AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2586-2597.	1.9	69
68	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016, 36, 889-902.	1.1	6
69	Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: Application for a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1029-1030, 60-67.	1.2	5
70	Combining "Bottom-Up" and "Top-Down" Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. <i>Clinical Pharmacokinetics</i> , 2016, 55, 823-832.	1.6	17
71	Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 845-853.	0.6	10
72	Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. <i>Xenobiotica</i> , 2016, 46, 1133-1141.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. <i>Clinical Therapeutics</i> , 2016, 38, 348-357.	1.1	7
74	Validation and Application of an LC-MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine. <i>Journal of Chromatographic Science</i> , 2016, 54, 713-719.	0.7	7
75	Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. <i>Clinical Drug Investigation</i> , 2016, 36, 369-376.	1.1	3
76	Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 276-284.	2.8	20
77	Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects. <i>Pharmacotherapy</i> , 2015, 35, 586-599.	1.2	8
78	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 1483-1492.e1.	1.1	20
79	Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 300-312.	1.2	2
80	Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 976-977, 78-83.	1.2	12
81	A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 84-92.	0.8	2
82	Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Ascending Doses of RCT-18 in Chinese Patients with Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1033-1044.	1.6	12
83	Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. <i>Clinical Therapeutics</i> , 2014, 36, 1196-1210.	1.1	11
84	LC-MS-MS Method to Simultaneously Determine Six Probe Drugs for CYP450 Isozymes in Human Liver Microsomes. <i>Chromatographia</i> , 2014, 77, 913-922.	0.7	3
85	Determination of phenylephrine in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 915-916, 28-32.	1.2	22
86	Simultaneous determination of blonanserlin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 939, 59-66.	1.2	8
87	Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 743-748.	1.2	39
88	Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2010, 30, 221-228.	1.1	5
89	Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3781-3786.	1.2	31
90	Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 39-49.	1.0	48

#	ARTICLE	IF	CITATIONS
91	Single-Dose and Multiple-Dose Pharmacokinetics and Safety of Telbivudine After Oral Administration in Healthy Chinese Subjects. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 999-1007.	1.0	23